{4-[4-(trifluoromethyl)benzyl]phenyl}methanol | 613240-15-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {4-[4-(trifluoromethyl)benzyl]phenyl}methanol
• 英文别名: [4-(4-Trifluoromethyl-benzyl)-phenyl]-methanol；[4-[[4-(trifluoromethyl)phenyl]methyl]phenyl]methanol
• CAS: 613240-15-6
• 化学式: C₁₅H₁₃F₃O
• 分子量: 266.263
• InChiKey: ZABYFMPEEYJQFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {4-[4-(trifluoromethyl)benzyl]phenyl}methanol 在 氯化亚砜 作用下， 生成 chloro-[4-(4-trifluoromethyl-benzyl)-phenyl]-methane
  参考文献：
  名称：

  Compounds that modulate PPAR activity and methods for their preparation

  摘要：

  该发明揭示了可以改变PPAR活性的化合物。该发明还揭示了这些化合物的药用可接受盐、含有这些化合物或其盐的药用可接受组合物，以及将它们用作治疗或预防哺乳动物的失脂血症、高胆固醇血症、肥胖症、进食障碍、高血糖、动脉粥样硬化、高甘油三酯血症、高胰岛素血症和糖尿病的治疗剂的方法，以及在哺乳动物中抑制食欲和调节瘦素水平的方法。本发明还揭示了制备所述化合物的方法。

  公开号：

  US20030225158A1
• 作为产物：
  描述：

  methyl 4-(4-(trifluoromethyl)benzyl)benzoate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以86%的产率得到{4-[4-(trifluoromethyl)benzyl]phenyl}methanol
  参考文献：
  名称：

  Compounds that modulate PPAR activity and methods for their preparation

  摘要：

  该发明揭示了可以改变PPAR活性的化合物。该发明还揭示了这些化合物的药用可接受盐、含有这些化合物或其盐的药用可接受组合物，以及将它们用作治疗或预防哺乳动物的失脂血症、高胆固醇血症、肥胖症、进食障碍、高血糖、动脉粥样硬化、高甘油三酯血症、高胰岛素血症和糖尿病的治疗剂的方法，以及在哺乳动物中抑制食欲和调节瘦素水平的方法。本发明还揭示了制备所述化合物的方法。

  公开号：

  US20030225158A1

文献信息

• Copper‐mediated simple and direct aerobic oxidative esterification of arylacetonitriles with alcohols/phenols
  作者：Jianyu Dong、Xiuling Chen、Fangyan Ji、Lixin Liu、Lebin Su、Min Mo、Jian‐Sheng Tang、Yongbo Zhou

  DOI：10.1002/aoc.6073

  日期：2021.1

  A simple and direct aerobic oxidative esterification reaction of arylacetonitriles with alcohols/phenols is achieved in the presence of a copper salt and molecular oxygen, which produces a broad range of aryl carboxylic acid esters in good to high yields. Copper salt plays multiple roles in the transformation, which allows the oxygenation of CH bond, cleavage of inert CC bond, and formation of CO

  在铜盐和分子氧的存在下，芳基乙腈与醇/酚的简单直接的好氧氧化酯化反应得以实现，从而以良好或高收率生产了多种芳基羧酸酯。铜盐起着变换，这允许C的氧合多个角色 H键的，惰性的C裂解 C键，C和形成一锅O键而没有任何的酸，碱，配体的帮助下，等等。该反应提供了从容易获得的起始原料向官能化的酯，特别是苯甲酸芳基酯的简单，直接和有效的方案。
• COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION
  申请人：Auerbach J. Bruce

  公开号：US20050153996A1

  公开（公告）日：2005-07-14

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

  本发明揭示了能够改变PPAR活性的化合物。本发明还揭示了这些化合物的药学上可接受的盐，包含这些化合物或其盐的药学上可接受的组合物，以及将它们用作治疗或预防哺乳动物的失脂症、高胆固醇血症、肥胖症、进食障碍、高血糖、动脉硬化、高三酰甘油血症、高胰岛素血症和糖尿病的治疗剂的方法，以及在哺乳动物中抑制食欲和调节瘦素水平的方法。本发明还揭示了制备所述化合物的方法。
• Synthesis and Structure–Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6<i>S</i>)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazine (PA-824)
  作者：Brian D. Palmer、Hamish S. Sutherland、Adrian Blaser、Iveta Kmentova、Scott G. Franzblau、Baojie Wan、Yuehong Wang、Zhenkun Ma、William A. Denny、Andrew M. Thompson

  DOI：10.1021/jm501608q

  日期：2015.4.9

  Novel extended side chain nitroimidazooxazine analogues featuring diverse linker groups between two aryl rings were studied as a potential strategy to improve solubility and oral activity against chronic infection by Mycobacterium tuberculosis. Both lipophilic and highly polar functionalities (e.g., carboxamide, alkylamine, piperazine, piperidine, but not sulfonamide) were well tolerated in vitro, and the hydrophilic linkers provided some solubility improvements, particularly in combination with pyridine rings. Most of the 18 compounds further assessed showed high microsomal stabilities, although in the acute infection mouse model, just one stilbene (6-fold) and two pyridine-containing acetylene derivatives (5-fold and >933-fold) gave in vivo efficacies notably superior to the clinical stage compound pretomanid (PA-824). The most efficacious analogue also displayed outstanding in vivo activity in the stringent chronic model (up to 24-fold better than the drug delamanid and 4-fold greater than our previous best phenylpyridine candidate), with favorable pharmacokinetics, including good oral bioavailability in the rat.
• USRE039916E1
  申请人：——

  公开号：——

  公开（公告）日：——
• US6964983B2
  申请人：——

  公开号：US6964983B2

  公开（公告）日：2005-11-15